Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Haematology Oncology Division in the Department of Internal Medicine at Texas Tech University Health Sciences Centre (TTUHSC) and director of the University Medical Centre (UMC) Cancer Centre, has shared groundbreaking findings from the landmark CLEAR study (Clinical trial Comparing Lenvatinib with Everolimus or Pembrolizumab in Renal Cell Carcinoma).
The findings underscore the critical role of tumour size reduction in improving survival outcomes for patients with advanced renal cell carcinoma (aRCC).
The latest analysis, presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025), further solidifies the effectiveness of the lenvatinib and pembrolizumab combination in treating this aggressive form of kidney cancer.
Hutson played a key role in the study and provided insights into the impact of these findings.
“This analysis reinforces that greater tumour shrinkage correlates with improved survival outcomes,” Hutson said.
“We now have compelling evidence that reducing overall tumour burden not only extends survival but also enhances the effectiveness of subsequent treatments, setting patients up for better long-term prognoses.”
The study, which initially led to the FDA approval of lenvatinib plus pembrolizumab for advanced renal cell carcinoma in 2021, continues to provide valuable insights into treatment strategies.
The new findings demonstrate that patients with greater reductions in total tumour size at disease progression had significantly longer median survival rates.
Additionally, data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) show that patients receiving the combination therapy were more likely to maintain or improve their IMDC risk scores, further supporting the regimen’s impact on long-term survival.
“These findings emphasise the importance of aggressive tumour reduction in the fight against renal cell carcinoma,” Hutson added.
“The data suggest that this combination therapy offers the best outcomes among currently available treatments, making it a strong contender for first-line treatment in advanced renal cell carcinoma.”
TTUHSC and UMC Health System remain committed to advancing cancer treatment and improving patient outcomes through innovative research and clinical excellence.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.